Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8201-8210 Newer>

Pharmaceutical Executive January 1, 2012 Bill Drummy	Scared to Death The pharma industry's risk-aversion is risking its survival. Where did the courage to innovate go?
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
The Motley Fool January 6, 2012 Brian Orelli	Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate.
The Motley Fool January 6, 2012 David Williamson	Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares.
The Motley Fool January 6, 2012 Sean Williams	Integra LifeSciences Shares Plunged: What You Need to Know Shareholders of medical device maker Integra LifeSciences are falling off their second cliff in as many quarters, down 17%, after the company issued disappointing preliminary fourth-quarter and full-year guidance.
The Motley Fool January 5, 2012 Anand Chokkavelu	Can Varian's Stock Be Cheap by the Numbers? Let's take a look.
The Motley Fool January 5, 2012 Brian Orelli	Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today.
The Motley Fool January 5, 2012 Brian Orelli	An Ugly Biotech Chart M&A expectations will do that.
The Motley Fool January 5, 2012 David Williamson	Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%.
The Motley Fool January 4, 2012	A Brief History of Becton, Dickinson's Returns While the past decade has seen valuations contract, the coming decade could see stable, even expanding, valuations.
<Older 8201-8210 Newer> Return to current articles.